Global Monovaccine
(Epstein-Barr Virus) Market potential, by Application (Mononucleosis,
Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple
sclerosis, and Nasopharyngeal Carcinoma) and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be US$
2.0 Bn.
Frequent research and development
activities and funding by various organizations is expected to lead to the
development of monovaccine in future. Currently, there is no licensed vaccine
for EBV. However, various universities and organizations are taking efforts to
develop novel vaccines and fulfill unmet needs. For instance, in March 2017,
Cancer Research U.K. completed its phase 1b clinical trial of (Modified
Vaccinia Ankara) MVA-EBNA1/LMP2 vaccine. It is being treated on nasopharyngeal
cancer patients with positive Epstein-Barr virus infection. In 2017,
researchers from the University of Kansas School of Engineering and School of
Pharmacy analyzed the genetics of human immune responses to develop basis of an
effective vaccine or drug therapy against Epstein-Barr virus or EBV, the
pathogen that causes infectious mononucleosis and infects around 90% of adults
worldwide. In January 2019, researchers and scientists from the German Cancer
Research Center developed a new strategy for creating a vaccine that targets
different EBV virus life phases and has the potential to provide effective
protection against EBV infection. Hence, frequent monovaccine development
efforts by various universities is expected to result in development of novel
vaccines and fulfill unmet needs in the near future.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2002
Browse 10 Market Data Tables and
10 Figures spread through 84 Pages and in-depth TOC on Global Monovaccine
(Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s
lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and
Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe,
Asia Pacific, the Middle East, and Africa)
Various government organizations
from different regions are taking efforts for the development of novel
monovaccines (Epstein - Barr virus) and gaining approval. For instance, in
2019, researchers from National Institutes of Health’s (NIH) National Institute
of Allergy and Infectious Diseases (NIAID) determined how various antibodies
induced by Epstein-Barr virus (EBV) block infection of cells grown in the
laboratory. Researchers used this information for development of novel vaccine
candidates in animals, elicited potent anti-EBV antibody responses that blocked
infection of cell types involved in EBV-associated cancers.
Key Takeaways of the Global
Monovaccine (Epstein-Barr virus) Market:
Currently, there is no approved
monovaccines in any region. However, various universities are involved in
robust research and development activities for monovaccines.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/mono-vaccines-epstein-barr-virus-market-2002
High prevalence of Epstein-Barr
virus infections is expected to rise the demand for its vaccine in future. For
instance, according to the study published by Cincinnati Children's Hospital
Medical Center, in 2018, Epstein-Barr virus is a very common virus in the U.S.
and other developed regions.
Emerging economies are expected
to be more potential regions for vaccine, as chances of infection with EBV are
high. For instance, according to the study published by Cincinnati Children's
Hospital Medical Center, in 2018, around 90% of the population becomes infected
with EBV virus by age 20. In emerging economies, 90% of people are infected by
age of 2 years.
Furthermore, Asia Pacific is
expected to be a potential market for nasopharyngeal cancer vaccine as the
prevalence of nasopharyngeal cancer is high in Asia Pacific. For instance,
according to American Cancer Society, nasopharyngeal cancer is more common in
several regions including South Asia, Middle East, and North Africa. In some
parts of China, there are as many as 21 cases per 100,000 people. The disease
is also more common among Inuit of Alaska and Canada.
Universities and organizations
involved in development of monovaccine (Epstein-Barr virus) include Cancer
Research U.K., National Institutes of Health, Chinese University of Hong Kong,
Genome Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer Research
Institute, and University of Minnesota.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2002
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment